Tumor-infiltrating lymphocytes make inroads in non–small-cell lung cancer

[1]  Jiqiang Yao,et al.  Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial , 2021, Nature Medicine.

[2]  G. Altan-Bonnet,et al.  Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer , 2020, Science.

[3]  Nicolai J. Birkbak,et al.  The T cell differentiation landscape is shaped by tumour mutations in lung cancer , 2020, Nature Cancer.

[4]  P. Sharma,et al.  Dissecting the mechanisms of immune checkpoint therapy , 2020, Nature Reviews Immunology.

[5]  Cheryl F. Lichti,et al.  MHC-II neoantigens shape tumor immunity and response to immunotherapy , 2019, Nature.

[6]  Daniel E. Speiser,et al.  Intratumoral Tcf1+PD‐1+CD8+ T Cells with Stem‐like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy , 2019, Immunity.

[7]  S. Rosenberg,et al.  A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus–associated Epithelial Cancers , 2018, Clinical Cancer Research.

[8]  J. Gartner,et al.  Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer , 2018, Nature Medicine.

[9]  J. Gartner,et al.  T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. , 2016, The New England journal of medicine.

[10]  S. Rosenberg,et al.  Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer , 2014, Science.

[11]  S. Rosenberg,et al.  Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Rosenberg,et al.  Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go? , 2006, Nature Clinical Practice Oncology.